Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BARDA Seeks Applications for Developing At-Home COVID-19 Diagnostics and Technologies

by Global Biodefense Staff
October 20, 2021
BARDA Seeks Applications for Developing At-Home COVID-19 Diagnostics and Technologies

Courtesy of BARDA

The U.S. Government program is now accepting submissions to develop diagnostics to detect SARS-CoV-2 acute infection as part of a new “COVID-19 At Home Diagnostics” program.

The Biomedical Advanced Research and Development Authority (BARDA) has opened a new area of interest under the EZ Broad Agency Announcement (EZ-BAA) solicitation to develop rapid and affordable home-based diagnostics to detect SARS-CoV-2 acute infection and supportive technologies which help enable more widespread, decentralized testing.

At-home diagnostics can empower individuals with better knowledge about their infection status, and ultimately reduce community transmission.

Through this opportunity, BARDA aims to advance the maturity of simpler tests that are inexpensive and easy to use. For more advanced tests, BARDA anticipates achievement of U.S. Food and Drug Administration (FDA) Emergency Use Authorization within six months. The ideal candidates would leverage existing manufacturing capabilities and be available to the public through the over-the-counter market.

BARDA is also seeking technologies that enable more convenient, widespread, and decentralized COVID-19 testing, or that improve on the current limitations of at-home diagnostic sensitivity, specificity and performance.

Early on during the pandemic, BARDA accepted applications through the EZ-BAA for COVID-19 antigen and molecular tests, which led to approximately 30 partnerships, 26 EUAs, and 140 million tests shipped. Reducing the barrier to testing is critical to equipping individuals with actionable health information when COVID-19 symptoms first occur so that they can self-isolate and seek medical care, thus helping to suppress the pandemic curve.

The initiative is sponsored by BARDA’s Divisions of Research, Innovation, and Ventures (DRIVe) and Detection, Diagnostics, and Devices Infrastructure (DDDI).

For additional information, see solicitation AOIs 11A: Home-based, Over-the-Counter Diagnostics for the Detection of SARS CoV-2 and 11B: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection in the Special Instructions 014 Issuance of the EZ-BAA (BAA-20-100-SOL-0002). Abstracts may be submitted until 5:00PM ET on January 15, 2022.

Tags: ASPRBAABARDACOVID-19Editor PickHHSRapid DiagnosticsRequest for ProposalsSARS-CoV-2

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC